In recent years, many surgical innovations have been made from cervical cancer, such as trachelectomy, laparoscopic radical hysterectomy and surgery for advanced or recurrent cervical cancer, etc. The surgical innovations improve treatment effects, as well as postoperative quality of life.

This paper reports the treatment of 65 cases with Verruca Acuminate, 35 cases with the fulguration while 30 cases with the combined fulguration with injection poly i:c and both were compared. The results showed that the cure rate of the fulguration group was 68.6%, and that of the combined therapy group was 96,5%. The cure rate of the latter group revealed higher (P

The treatment for endometrial cancer refers to surgery,radiation and chemotherapy.Some disputable issues in the treatment are existing.Based on the recent clinical trial results,the choice of surgical modality,the role of lymphadenectomy,radiation and chemotherapy are present and discussed in this article.

OBJECTIVE:To establish a HPLC method for determination of the principal components and the related substances in compound ftibamzone/dyclonine liniment. METHODS: The determination was performed on MACHEREY-NAGEL C18 chromatographic column with the mobile phase consisted of methanol-acetonitrile-0.02 mol?L-1 potassium dihydrogen phosphate solution-triethylamine (25∶25∶50∶0.3,pH value adjusted to 4.0 by the phosphoric acid) with a flow rate of 1.0 mL?min-1. The UV detection wavelength was set at 295 nm. RESULTS: A baseline separation was achieved between foreign materials’ peaks and the principal agents’ peaks. The calibration curve of ftibamzone and dyclonine were linear within the ranges of 20.63～72.21 ?g?mL-1(r=0.999 9) and 20.44～71.54 ?g?mL-1 (r=0.999 9),respectively;the average recovery rate was 98.7% vs. 99.2%;the inter-day RSD was 0.97% vs. 1.10%;the intra-day RSD was 1.52% vs. 1.75%,and the lowest detective limit was 0.4 ng vs. 0.2 ng. The contents of the related substances were ranged from 0.43% to 0.68%. CONCLUSION: This method is simple,rapid,specific,accurate and reproducible,and it can be used for the quality control of the compound ftibamzone/dyclonine liniment.

Purpose:To study the adjuvant therapy in uterine sarcomas,to decrease local recurrence and metastases and improve survival.Methods:Analysis of the management of 113 cases of uterine sarccoma , retrospectively. 30 cases were treated weith surgery alone , 25 with adjuvance radiation , 34 with postoperative chemotherapy, 21 with surgery and chemo radiation.Results:The 2 year pelvic recurrence and metastases with surgery alone were 43.3 % and 30 0 %,32 0 % and 28 0 % with postoperative radiation,44.1 % and 20.6 % with postoperative chemotherapy, 23.8 % and 23.8 % with postoperative combination of chemo radiation.But there was no significant difference between surgery alone and postoperative adjuvant therapy.Conclusions:Postoperative radiotherapy can improve local control,adjuvant chemotherapy can decrease metastases,both can improve disease free survival,but can not improve overall survival for uterine sarcomas.

Despite multimodel chemotherapy after successful surgical cytoreduction for ovarian cancer,disease recurrence continues to be problematic.Therefore,exploring new treatment strategy has already become urgent matter of the moment. Biological targeted therapies have been studied to overcome chemotherapy resistance.The most promising one at this time is bevacizumab.Results from phase Ⅱ and phase Ⅲ trials were excited.Deeper understanding of biologic pathway in ovarian cancer,and more biologic targets undergoing clinical trial will develop a new world for the treatment of ovarian cancer.

Purpose:To study the role of postoperative radiotherapy in early stage uterine sarcomas. Methods:Retrospective analysis of the impact of radiotherapy on progress-free survival rate (PRS )rate, local recurrence rate (LRR) and overall survival (OS)in stage Ⅰ,Ⅱ uterine sarcomas. 34 cases were treated with surgery alone ,42 cases were treated with postoperative radiotherapy. Results:The PRS at 2 and 5 years for surgery were 38.2% and 26.5% ,69.0% and 57.1%for postopeative radiotherapy. The LRR at 2 and 5 years treated with surgery were 52.9% and 64.7%,26.2% and 28.6% with adjuvant irradiation. The OS at 2 and 5 years treated with surgery were 83.4%and 47.0%,83.3% and 69.0% with adjuvant radiation. Conclusions:Postoperative radiotherapy showed a marked increase in the three parameters studied (PRS? LRR?OS ) for I,II stage uterine sarcomas.

Objective To study the clinical feature and treatment of lung benign metastasizing leiomyoma. Methods A retrospective analysis was performed on 2 cases of lung benign metastasizing leiomyoma. Results Two cases were asymptomatic who also had previously undergone hysterectomy, but imageology revealed multiple pulmonary nodules bilaterally of various sizes. And one of them had a pelvic mass. Conclusion Lung benign metastasizing leiomyoma is a rare disease. Hysterectomy, bilateral salpingo-oophorectomy and hormonal therapy may be helpful to improve the prognosis.

The pharmacodynamics of prostaglandin E1 (PGE1) administered by different routes to rats was investigated in this paper. The hypotensive effect of PGE1 was used as an index of drug efficacy, pharmacodynamic parameters such as time to reach peak effect (Tmax), maximal percentage of blood pressure decrease (Emax, %), duration of effect (Td), and the area determined after PGE1 given to rats intranasally, sublingually, intraperitoneally (ip),and intramuscularly (im), separately, and compared with those obtained from intravenous (iv) administration. Similar to iv route, the pharmacodynamic parameters of PGE1 from the other administration routes, Emax, Td and in particular AUC values were all increased with increasing doses, showing dose-efficacy relationship. Tmax was found to be approximately 3-4 min for nasal route, 3-8 min for im, 6-8 min for ip and 12-30 min for sublingual route, separately. Thus, the order of magnitude of absorption rate of the drug was as follows: nasal≈im＞ip＞sublingual. If the pharmacological bioavailability (PF) for each administration route was used as a tentative measure of drug absorption extent, the order of magnitude of absolute bioavailability appeared as follows: nasal＞im≈ip＞sublingual. Furthermore, the interindividual difference was found to be larger for im and ip route than that for nasal and sublingual route. These results indicate nasal and sublingual routes are two promising routes for the systemic delivery of PGE1 in clinical applications.

Purpose:To evaluate the efficacy and toxicities of gemcitabine plus cisplatin for patients with relapsed ovarian cancer. Methods:Twenty-eight patients with recurrent ovarian carcinoma received gemcitabine (1000 mg/m~(2)) plus cisplatin (35 mg/m~(2)) on days 1 and 8 of each 21-day cycle. Of 28 patients, sixteen who relapsed within six months of previously platinum-based regimen were platinum-resistant and the other twelve were platinum-sensitive. Results:Of 28 patients, there were 5 (17.9%) complete and 12 (42.9%) partial responses, for an overall response rate of 60.7% (95%CI: 41.7%–79.6%). The median time to progression for objective responders was 5.5 months with a range of 2.5 to 20 months. Median overall survival for all 28 patients was 12.5 months. Among 16 platinum-resistant patients, a 56.3% response rate occurred. The median survival time was 10.5 months. Among 12 platinum-sensitive patients, a 66.7% response rate occurred. The median survival time was 14.5 months. There were leukopenia grade Ⅲ in 35.7%, grade Ⅳ in 17.9%; thrombocytopenia grade Ⅲ in 28.6 %, grade Ⅳ in 14.3% of patients. Conclusions:Cisplatin plus gemcitabine is active in patients with relapsed ovarian cancer. The adverse effects are tolerable. Hematologic toxicities are manageable with dose modifications.